top of page

Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology

Feb 2

1 min read

She discusses the GABA-aminotransferase inhibitor, OV329, and KCC2 programs.

https://vimeo.com/1161225612?share=copy&fl=sv&fe=ci

Recent Posts

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

Earlier this month, Agilent agreed to acquire Philadelphia based Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more

Earlier this month, Agilent agreed to acquire Philadelphia based Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page